The chitinase 3-like 1 gene (CHI3L1) is abnormally expressed in the hippocampus of subjects with schizophrenia and may be involved in the cellular response to various environmental events that are reported to increase the risk of schizophrenia. Here, we provide evidence that the functional variants at the CHI3L1 locus influence the genetic risk of schizophrenia. First, using case-control and transmission/disequilibrium-test (TDT) methodologies, we detected a significant association between schizophrenia and haplotypes within the promoter region of CHI3L1 in two independent cohorts of Chinese individuals. Second, the at-risk CCC haplotype ( and .0018 in case-control and TDT studies, P p .00058 respectively) revealed lower transcriptional activity (
Schizophrenia (MIM 181500) is a common, complex major mental disorder affecting ∼1% of the population worldwide. 1 Clinical and epidemiological investigations indicate that schizophrenia is a multifactorial disorder with genetic and environmental elements contributing to overall risk. 2 A number of environmental factors, including obstetric complications, prenatal exposure to infection or famine, and psychosocial stressors, have been reported as risk factors of schizophrenia. [2] [3] [4] [5] An adverse environment can produce physiological and/or psychological stress, which, in turn, may result in brain dysfunctions. A key period of vulnerability to environmental stress may be during brain development. This is consistent with current concepts that view schizophrenia as primarily a disorder of neurodevelopment. 6 However, sensitivity to environmental stressors shows substantial interindividual variation, and at least part of this variation may be genetic in origin and/or involve gene-environment interactions.
The chitinase 3-like 1 gene (CHI3L1 [MIM 601525]), located on chromosome 1q32.1, a region that shows weak linkage to schizophrenia, 7 has been reported to display disease-specific alteration in gene expression in the hippocampus of patients with schizophrenia. 8 One function of CHI3L1 is to act as a cellular survival factor in response to an adverse environment: various types of physiological stress, such as inflammation, hypoxia, and nutrient deprivation, may induce high expression of CHI3L1. 9, 10 The presence of CHI3L1 protein inhibits the activity of ASK1, 11 which is pivotal for the transmission of stress-induced cellular responses, and protects the cells from undergoing apoptosis.
Here, we present evidence that CHI3L1 contributes to the genetic risk factors of schizophrenia. We have observed significant association between schizophrenia and genetic variations in the CHI3L1 locus in both familybased and population-based investigations. Moreover, the CHI3L1 haplotypes implicated in schizophrenia susceptibility were associated with the altered expression level of the gene. Cis-acting effects of the functional variants in CHI3L1 may be responsible for the association.
Material and Methods

Subjects
For the case-control investigation, 412 unrelated patients with schizophrenia and 464 control individuals were recruited in this study. The patient group consisted of 200 men and 212 women with a mean ‫ע‬ SD age of 41.13 ‫ע‬ 12.97 years. The control group consisted of 200 men and 264 women with a mean age of 34.88 Figure 1 . Genomic structure of CHI3L1 and the location of SNPs included in the present study.
‫ע‬ 10.37 years. A subgroup of samples including 29 patients (15 men and 14 women with a mean age of 39.68 ‫ע‬ 12.66 years) and 54 controls (27 men and 27 women with a mean age of 39.66 ‫ע‬ 11.99 years) was used to investigate gene expression. All the population-based samples were from Shanghai, East China. For the transmission/disequilibrium-test (TDT) study, 308 unrelated probands with schizophrenia and their biological parents were recruited. The probands consisted of 163 males and 145 females with a mean age of 24.0 ‫ע‬ 6.6 years, of whom 128 were from Shanghai, 65 from Xi'an, 35 from Changchun, and 80 from Jilin. Subjects with schizophrenia were given strict diagnoses according to the criteria of the DSM-IV, with the use of a combination of examination of psychiatric case records and clinical interviews, which used the Chinese version of the Schedule for Affective Disorders and Schizophrenia-Lifetime (SADS-L). The diagnoses were checked and verified by another independent senior psychiatrist who reviewed the psychiatric case records. A total of 1,800 subjects, including 720 patients with schizophrenia, were recruited in this study. All subjects were Han Chinese in origin. Participants gave a standard informed consent in the protocol, which was reviewed and approved by the Shanghai Ethical Committee of Human Genetic Resources, after the nature of the study had been fully explained.
Genotyping
All five SNPs were selected from dbSNP. SNP1, SNP2, and SNP5 were scored using a single-nucleotide primer extension (SNuPe) method with MegaBACE SNuPe genotyping kit (Amersham Biosciences) and the primers that anneal 1 b upstream of the target SNPs. A complementary-labeled dideoxynucleotide triphosphate was added at the SNP site in the reaction. The SNuPe products were then cleaned and were electrophoresed on MegaBACE 1000 instruments (Amersham Biosciences). SNP3 and SNP4 were genotyped using direct sequencing on ABI 3100 instruments (Applied Biosystems).
Cell Culture, Transfection, and MYC-Inhibitor Trial
U251 cells were cultured in Dulbecco's modified Eagle medium (Gibco-BRL) with 10% fetal bovine serum (FBS) and penicillinstreptomycin at 37ЊC and 5% CO 2 . Transient transfection for the luciferase reporter assay was performed in a 48-well plate with use of LipofectAmine 2000 regent (Invitrogen), and pCBR control vector (Promega) was used to correct for transfection efficiency. For each well, 0.2 mg pCBG99 plasmid (Promega) containing a 1.3-kb CHI3L1 promoter fragment and 0.2 mg pCBR control plasmid were added. The Chroma-Glo luciferase assay system (Promega) was used to measure the relative transcriptional activities of the CHI3L1 haplotypes after they were cultured for 36 h. THP-1 cells were maintained in RPMI 1640 medium (Gibco-BRL) supplemented with 10% FBS and penicillin-streptomycin. To selectively block the MYC signaling pathway in U251 and THP-1, cells were cultured for 72 h in the corresponding mediums containing 64 mM MYC inhibitor and 2.5% FBS.
Nuclear-Extraction Preparation and Electrophoretic Mobility Shift Assay
Nuclear proteins were extracted using NE-PER Reagents (Pierce). Electrophoretic mobility shift assays (EMSAs) were performed using gel shift assay systems (Promega) under the guidelines provided. Oligonucleotides were end-labeled with [g-32 P ] ATP with use of T4 polynucleotide kinase. The binding reaction contained 8 mg of nuclear-extract proteins, 1# binding buffer, and, if needed, unlabeled competitors; labeled probes were added after 10 min, and samples were incubated at room temperature for a total of 30 min. For the supershift assay, nuclear-extract proteins, labeled probes, and antisera were incubated for 16 h at 4ЊC. Samples were analyzed by electrophoresis on 4% (w/v) native polyacrylamide gels. The gels were dried and were autoradiographed for 3 h or overnight.
RNA Extraction and cDNA Synthesis
Total RNA was extracted using Trizol reagent. RNA integrity was confirmed by direct visualization of 18S and 28S rRNA bands after agarose-gel electrophoresis. RNA samples were incubated using 10 units of DNase I (Novagen) at 37ЊC for 20 min to remove residual DNA, followed by inactivation at 65ЊC for 10 min. RNA samples were further purified using a HiBind spin column (Omega) in accordance with the manufacturer's instructions. The purified RNA samples (0.5 mg) were then reverse transcribed using the SuperScript first-strand synthesis system (Invitrogen) and random hexamers.
Real-Time Quantitative PCR and Allele-Specific Expression Assay
Real-time PCR was performed using the ABI7900 system (Applied Biosystems). Reactions were performed in a 10-ml volume including diluted cDNA samples, primers, and SYBR Green I Mastermix (Applied Biosystems). Diluted cDNA samples produced from 10 ng total RNA were added to each well. Real-time PCR data were collected using SDS software (version 2.1 [Applied Biosystems]). Expression of CHI3L1 was normalized in relation to GAPDH levels (denoted as DCt).
Both GAPDH and CHI3L1 were tested four times for each sample. SNP5 within exon 5 was used as a marker for the allele-specific expression assay. The SNuPe method was used to compare relative allelic expression in individual subjects who were heterozygous for the marker polymorphisms. To normalize the signal from different fluorescent dyes, genomic DNA with a perfect 1:1 ratio of the two alleles was used to correct allelic ratios obtained from each cDNA analysis. The SnuPe products of DNA and cDNA templates from the same samples were electrophoresed in the same capillaries in one run, by multiple injections.
Risperidone Trial
Risperidone (Xian Janssen-Cliag) was dissolved in saline and was administered to C57Bl/6 mice (1 mg/kg) daily. Control mice received the vehicle alone. All the mice were housed, five per cage, at room temperature with a 12-h light/dark cycle. For each group, 5 male and 5 female mice were included. Mice received risperidone or the vehicle for 3 wk and were killed 2 h after the final trial. Luciferase reporter assay of SNP2, SNP3, and SNP4 common haplotypes in U251 cells. The transcriptional activity of the pCBG99 control was set at 100%. Each CHI3L1 haplotype was tested eight times. Among the haplotypes, the risk haplotype (CCC) revealed the lowest activity, whereas the protective haplotype (TTG) showed the highest activity ( , by one-way Ϫ7 P p 2.2 # 10 ANOVA).
Statistical Analysis
A SHEsis 12 software platform was used to analyze deviation from Hardy-Weinberg equilibrium, pairwise linkage disequilibrium (LD), and genetic association of the polymorphisms in the casecontrol study. For TDT analysis, the TDTPHASE 13 program of the UNPHASED set was used for single and multiple marker-haplotype transmission analyses and for estimating the LD between the adjacent markers. Group comparisons for the dual luciferasereporter genes assay, expression analyses, and comparative allele representation were analyzed using an unpaired two-tailed t test or a Mann-Whitney U test or, if there were more than two groups, a one-way ANOVA or Kruskal-Wallis H test.
Results
The CHI3L1 gene spans 8 kb in the human genome. We selected markers from the dbSNP database and used sequencing to screen new polymorphisms in 16 individuals. We typed five SNPs at the CHI3L1 locus ( fig. 1 ) in 412 patients with schizophrenia and 464 unaffected controls. The genotypic distributions of all the markers were in accordance with Hardy-Weinberg equilibrium ( ) in P 1 .05 each set of samples. SNP5 was the only common variant present in the coding sequences, but there was no difference in the allelic frequency between patients and controls. However, three SNPs (i.e., SNP2, SNP3, and SNP4) in the promoter region of the gene revealed allelic association with schizophrenia (table 1) . To attempt to confirm these findings, we performed the TDT in a fully independent cohort of 311 proband-parent triads. We found significant transmission distortions of SNP3 and SNP4 but failed to replicate the association of SNP2. r p 0.75 family-based samples, respectively), the positive result of SNP2 in the case-control study could be explained as LD with SNP3. However, the association results of SNP3 and SNP4 appear to be independent of each other ( ).
2 r ! 0.1 In haplotypic analysis, three common haplotypes (with probability 13%) constructed from SNP2, SNP3, and SNP4 were observed (table 1). The CCC haplotype was associated with higher risk of schizophrenia ( and P p .00058 .0018 in population-and family-based samples, respectively). The association remained significant in both casecontrol and TDT studies, even after a stringent Bonferroni correction ( , corrected for 16 tests) was applied. An-P ! .03 and .032 in population-and fam-P p .013 ily-based samples, respectively). We also determined that SNP3 was the tagging SNP (tSNP) of TTG, whereas SNP4 was the tSNP of CCC.
Genetic variations in the promoter region can influence gene expression by changing the rate of transcription. We cloned DNA fragments that contain the three common haplotypes constructed from SNP2, SNP3, and SNP4 into luciferase reporter vectors and compared their relative transcription activities in a human glioblastoma cell line (U251). The haplotypes implicated in schizophrenia susceptibility were associated with significant reporter-activity difference ( ) (see fig. 2 ). The risk hap-Ϫ7 P p 2.2 # 10 lotype CCC showed lower activity (28% lower) than the neutral haplotype CCG. By contrast, the protective haplotype TTG represented higher activity (47% higher) than CCG.
SNP3 and SNP4 are located in the core promoter region of CHI3L1. We used EMSAs to determine whether the genetic variants would alter DNA-protein interaction. The probes of both alleles of SNP3 produced one binding complex with U251 nuclear-extract proteins, but there was no difference between the two alleles ( fig. 3a) . As for SNP4, the C-allele probe generated one clear binding complex with nuclear extract, but the G-allele probe generated two. The additional complex with lower mobility can still remain visible after the 100# C-allele cross-competitor is loaded (fig. 3b) .
The SNP4 GrC transversion appeared to alter the consensus sequences of several transcription factors, on the basis of analyses with Genomatix software. 14 We predicted that MYC/MAX and AP-2 would be promising candidates and performed supershift analysis with use of the monoclonal antibodies to MYC and AP-2. The addition of either of these antibodies resulted in weakness of the G-allelespecific band; however, the intensity of the supershifted bands was too low for reliable visualization. Lengthening of the exposure time (overnight) enabled good observation of the supershift bands ( fig. 2c ). AP-2 is a negative regulator to MYC-mediated transcriptional activation when their binding sites are adjacent. 15 Hence, our further investigation was focused on the role of MYC/MAX in CHI3L1 transcription. We treated U251 and THP-1 (human monocytic cell line) cells with MYC inhibitor, which interfered with the interaction between MYC and MAX. 16 We detected a severely decreased CHI3L1 expression in both cell lines ( fig. 4) , which pointed to an active MYC/ MAX binding site in the promoter region of CHI3L1 being involved in controlling the expression of this gene. The SNP4 GrC polymorphism may, therefore, influence gene expression by impairing the MYC/MAX-regulated transcriptional activity. Meanwhile, similar results in the glialderived and lymphoid-derived cells indicated that the effect of SNP4 may be common in the blood and in the brain.
We used real-time PCR to quantify the gene expression ). d, Haplotypes in the promoter region of CHI3L1 associated with expression P ! .01 level of the gene in PBC. e, Relative allele-specific expression of the SNP5 data expressed as allele ratios of A/G. Patients who were heterozygotes for SNP4 revealed highly significant allele differences (t test , corrected for 5 tests) f, Risperidone-treated Ϫ6 P p 9.1 # 10 mice did not change the mRNA level of CHI3L1 in blood and brain (t test ). The expression level of CHI3L1 in untreated mice P 1 .05 was defined as 100.
in the peripheral blood cells (PBC) isolated from 82 individuals. The expression of CHI3L1 was decreased by 19% in 29 patients compared with its expression in 53 controls, but there was no statistically significant difference between the two groups ( ) (fig. 3a) . The samples P p .081 were then grouped together for analysis. The CHI3L1 expression level was obviously correlated with genotypes of SNP4 ( , corrected for 5 tests) ( fig. 5b ), as well Ϫ5 P p 4.2 # 10 as with genotypes of SNP3 ( , corrected for Ϫ4 P p 7.6 # 10 5 tests) ( fig. 5c ). We determined the precise haplotypic structures of the 82 samples by cloning and sequencing the DNA fragments containing SNP2, SNP3, and SNP4. There was a significant association between gene expression and common haplotypes ( , corrected Ϫ5 P p 3.1 # 10 for 5 tests) ( fig. 5d) .
To minimize the trans-acting influences, we performed an allele-specific expression assay, 17 using SNP5 as a marker for mRNA transcribed from each chromosomal allele.
The objective of the assay was to determine the allelespecific expression pattern of SNP4: the C alleles of SNP4 were almost always in linkage with the A alleles of SNP5 ( ), and, therefore, the comparative expression ra-D p 0.98 tio of A/G in SNP5 represented that of C/G in SNP4 for the samples that were heterozygous in both loci. In total, 33 samples that were heterozygous in SNP5 were used in the current assay. When the data from all the samples were combined, the comparative allelic ratios of A/G were widespread. However, in the six samples that were also heterozygous in SNP4, the expression of the A allele was significantly reduced by ∼80% compared with the G allele ( , corrected for 5 tests) ( fig. 5e ). This result In view of the possible effects on gene expression data from antipsychotic medication in the probands with schizophrenia, we examined the CHI3L1 expression level after risperidone treatment, since most patients recruited for the expression studies were receiving this treatment. Our results indicated that risperidone treatment does not change the CHI3L1 mRNA level in vivo ( fig. 5f ).
Discussion
In this study, we observed positive association between schizophrenia and genetic variations in the promoter region of the CHI3L1 gene in two independent cohorts of Chinese patients with schizophrenia. The association remained significant in both population-based and familybased investigations after correction for multiple tests. Our combined findings made it unlikely that they are the result of a type I error and ruled out the possibility that stratification could explain the results. However, we cannot formally exclude the possibility that the observed association signal originates from genes in the vicinity of the CHI3L1 locus and not from the CHI3L1 locus itself. Further detailed LD-mapping studies performed in different populations are essential. Nevertheless, CHI3L1 is a promising candidate gene for schizophrenia, and the parallel functional evidence reinforces our positive association findings. We have demonstrated that the individuals carrying risk alleles/haplotypes have lower expression levels of CHI3L1 than do those carrying protective alleles/haplotypes. The effect is also greater in individuals carrying two copies of the risk alleles/haploypes. Our results strongly indicate that susceptibility variants in the CHI3L1 locus are likely to exert their effect mainly by changing the abundance of gene production. Furthermore, SNP4, which gives the strongest association with schizophrenia, is a good candidate for such a susceptibility variant, since the GrC transversion impairs the MYC/MAX-regulated transcriptional activity, which, in turn, can account for the reduced expression of the risk haplotype.
The genetic variations that change the expression of CHI3L1 may influence some key processes that are CHI3L1-dosage dependent. One is activation of AKT-mediated signal pathways through phosphatidylinositol-3 kinase (PI-3K)-dependent phosphorylation. 18 There is strong convergent evidence indicating that the PI-3K/AKT signal pathway is implicated in schizophrenia; AKT1-GSK3b, a component of AKT-mediated signals pathway, is impaired in patients with schizophrenia, and antipsychotic medication may induce AKT activation, to compensate for the impairment. 19 An additional possibility is that CHI3L1 participates in the pathophysiology of schizophrenia through its function on the immune response. Activation of the inflammatory response system has been observed in schizophrenia and affective disorders. 20, 21 High levels of inflammatory cytokines, the immune mediators, have an effect on neuronal survival 22 and result in neurobehavioral deficits in animal models.
23 CHI3L1 may have an inhibitory effect on these inflammatory responses 24 and provides a negative-feedback control for the action of inflammatory cytokines. 10 These functional observations suggest a role of the CHI3L1 gene in preventing the progression of psychosis ( fig. 6 ), whereas the functional variations that reduce expression levels may increase the genetic risk of developing schizophrenia.
AKT and cytokines, as well as CHI3L1, play a role in cell response to an adverse environment; it has long been known that the production of inflammatory cytokines is stimulated by the stress coupled with adverse environmental events. 21 The AKT pathway has been strongly associated with cell survival 25, 26 and regulates the cytokineinduced cellular responses. 27 Certain genes involved in PI-3K/AKT and cytokine signaling have been reported to be associated with schizophrenia. 19, [28] [29] [30] It will be of interest to investigate the interaction between these genes and CHI3L1 under adverse environmental circumstances and the possible effects of epistasis between the genes on the genetic susceptibility to schizophrenia.
In conclusion, our findings identify CHI3L1 as a potential schizophrenia-susceptibility gene. Data from genetic and molecular analyses provide clear and consistent evidence for the functional SNP4 to be a strong candidate for a risk factor of schizophrenia. Moreover, our results, together with the previously published observations, support the proposal that genes involved in biological response to adverse environmental conditions play roles in the predisposition to schizophrenia.
